ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 373,53
0,95%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC
  6. International Stem Cell Corporation (QB) (ISCO)

  7. International Stem Cell Corporation (QB) (ISCO) Actualités

ISCO

International Stem Cell (QB) (ISCO)

International Stem Cell Corporation (QB)
De:
Trier par:
 Showing the most relevant articles for your search:USOTC:ISCO
DateHeureSourceTitreSymboleSociété
13/11/202322h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]USOTC:ISCOInternational Stem Cell Corporation (QB)
08/11/202319h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesUSOTC:ISCOInternational Stem Cell Corporation (QB)
27/09/202318h27Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsUSOTC:ISCOInternational Stem Cell Corporation (QB)
18/09/202314h01Edgar (US Regulatory)Form 8-K - Current reportUSOTC:ISCOInternational Stem Cell Corporation (QB)
21/06/202320h08Edgar (US Regulatory)Current Report Filing (8-k)USOTC:ISCOInternational Stem Cell Corporation (QB)
16/06/202323h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:ISCOInternational Stem Cell Corporation (QB)
12/05/202322h02Edgar (US Regulatory)Quarterly Report (10-q)USOTC:ISCOInternational Stem Cell Corporation (QB)
28/04/202322h31Edgar (US Regulatory)Annual Report to Security Holders (ars)USOTC:ISCOInternational Stem Cell Corporation (QB)
30/03/202322h37Edgar (US Regulatory)Annual Report (10-k)USOTC:ISCOInternational Stem Cell Corporation (QB)
27/04/202222h32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)USOTC:ISCOInternational Stem Cell Corporation (QB)
27/06/202000h07Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)USOTC:ISCOInternational Stem Cell Corporation (QB)
13/05/202019h35Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)USOTC:ISCOInternational Stem Cell Corporation (QB)
14/08/201923h07Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)USOTC:ISCOInternational Stem Cell Corporation (QB)
29/04/201914h30InvestorsHub NewsWireInternational Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical TrialUSOTC:ISCOInternational Stem Cell Corporation (QB)
16/04/201914h30InvestorsHub NewsWireInternational Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End ResultsUSOTC:ISCOInternational Stem Cell Corporation (QB)
07/03/201912h05Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:ISCOInternational Stem Cell Corporation (QB)
13/02/201914h30InvestorsHub NewsWireInternational Stem Cell Corporation Publishes Successful Results in Traumatic Brain InjuryUSOTC:ISCOInternational Stem Cell Corporation (QB)
15/01/201914h30InvestorsHub NewsWireInternational Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging BusinessUSOTC:ISCOInternational Stem Cell Corporation (QB)
05/12/201814h30InvestorsHub NewsWireInternational Stem Cell Corporation is Valued at $6.16 per Share by Edison Investment ResearchUSOTC:ISCOInternational Stem Cell Corporation (QB)
15/11/201814h30InvestorsHub NewsWireInternational Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018USOTC:ISCOInternational Stem Cell Corporation (QB)
05/11/201814h30InvestorsHub NewsWireInternational Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson's Disease Clinical TrialUSOTC:ISCOInternational Stem Cell Corporation (QB)
30/10/201813h30InvestorsHub NewsWireInternational Stem Cell Corporation to Present Clinical Data at the Society for Neuroscience Annual MeetingUSOTC:ISCOInternational Stem Cell Corporation (QB)
08/10/201814h30InvestorsHub NewsWireInternational Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical TrialUSOTC:ISCOInternational Stem Cell Corporation (QB)
02/10/201814h00InvestorsHub NewsWireInternational Stem Cell Corporation Raised Funds Through a Private Placement at Premium to MarketUSOTC:ISCOInternational Stem Cell Corporation (QB)
21/08/201813h00InvestorsHub NewsWireInternational Stem Cell Corporation Granted Key US Patent Protecting Lead Therapeutic ProgramUSOTC:ISCOInternational Stem Cell Corporation (QB)
15/08/201813h00InvestorsHub NewsWireInternational Stem Cell Corp Announces Record Sales and Operating Results for the Three and Six-Months ended June 30, 2018USOTC:ISCOInternational Stem Cell Corporation (QB)
15/08/201812h49Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)USOTC:ISCOInternational Stem Cell Corporation (QB)
10/07/201813h00InvestorsHub NewsWireInternational Stem Cell Corporation Expands Manufacturing Capabilities for Biomedical ProductsUSOTC:ISCOInternational Stem Cell Corporation (QB)
11/06/201813h00InvestorsHub NewsWireInternational Stem Cell Corporation Doses First Patient of the Third Cohort in Parkinson's Disease Clinical TrialUSOTC:ISCOInternational Stem Cell Corporation (QB)
05/06/201813h00InvestorsHub NewsWireInternational Stem Cell Corporation to Launch Advanced Joint SupplementUSOTC:ISCOInternational Stem Cell Corporation (QB)
 Showing the most relevant articles for your search:USOTC:ISCO

Dernières Valeurs Consultées

NASDAQ
NVDA
NVIDIA
EU
SGO
Cie de SaintGobain
EU
AF
Air FranceKLM
NASDAQ
AMZN
Amazon.com
EU
RI
Pernod Ricard
EU
ACA
Credit Agricole
EU
CAP
Capgemini
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
EU
LR
Legrand
EU
HO
Thales
EU
PX1
CAC 40
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés